Dermato-oncology has become a major player in the field of dermatology. Translational medicine research has accelerated the bench-to-bedside downtime, with new diagnostic methods and therapeutic agents that are changing the landscape of patient care.
Skin cancer morbidity and mortality continues to increase worldwide, placing a heavy human and economic burden on limited resources. Despite very significant advances in the treatment of keratinocyte cancers, melanoma and other more infrequent skin tumors, primary prevention and early diagnosis are the most efficient interventions to control this ‘epidemic’.
On November 2nd, 2017, the city of Buenos Aires, Argentina, hosted a group of international experts to discuss and update a number of relevant topics in dermato-oncology. The meeting was supported by an unrestricted educational grant from Pierre Fabre Dermo-Cosmétique/Laboratoires dermatologiques Avène, France. This journal supplement summarizes the presentations and discussions of that Meeting.
Renato Bakos (Porto Alegre, Brazil), Tatiana Pinto Blumetti (Sao Paulo, Brazil), Gabriel Salerni (Rosario, Argentina) and Rodrigo Roldán-Marin (Mexico City, Mexico) discussed the present status of “Noninvasive Imaging Tools in the Diagnosis and Treatment of Skin Cancers”, emphasizing their contribution to early diagnosis and the reduction of biopsies needed for a correct diagnosis; Raúl Cabrera and Francisca Recule (Santiago, Chile) presented their experience on “Unusual Clinical Presentations of Malignant Melanoma: A Review of Clinical and Histologic Features with Special Emphasis on Dermatoscopic Findings”. Early melanoma diagnosis is a challenge for everyone, more so when we face the infrequent or rare types. Abel Gonzalez (Buenos Aires, Argentina) shared his experience on “Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis”, a controversial, timely and balanced contribution. Mario Lacouture (New York, USA) and Vincent Sibaud (Toulouse, France) discussed the “Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails”. This new area of our specialty, of pathophysiological interest and patient management importance, has become a major challenge for those involved in patient care. I discussed sunscreens and the need for “Homeostasis in Topical Photoprotection: Getting the Spectral Balance Right”.
I believe all the participants in this meeting share a common interest with their colleagues: the best care for our skin cancer patients. We sincerely hope that the concepts presented herein will help you to do so.